Literature DB >> 12183257

In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach.

D T A Te Dorsthorst1, P E Verweij, J Meletiadis, M Bergervoet, N C Punt, J F G M Meis, J W Mouton.   

Abstract

Combination therapy could be of benefit for the treatment of invasive yeast infections. However, in vitro interaction studies are relatively scarce and the interpretation of the fractional inhibitory concentration (FIC) index can be contradictory due to various definitions used; not all information on the interaction study is used in the index, and different MIC end points exist for different classes of drugs. Fitting an interaction model to the whole response surface and estimation of an interaction coefficient alpha (IC(alpha)) would overcome these objections and has the additional advantage that confidence intervals of the interaction are obtained. The efficacy of flucytosine (5FC) in combination with amphotericin B (AB) and fluconazole (FCZ) was studied against 35 yeast isolates in triplicate (Candida albicans [n = 9], Candida glabrata [n = 9], Candida krusei [n = 9], and Cryptococcus neoformans [n = 8]) using a broth microdilution checkerboard method and measuring growth after 48 h by a spectrophotometer. The FIC index and IC(alpha) were determined, the latter by estimation from the response surface approach described by Greco et al. (W. R. Greco, G. Bravo, and J. C. Parsons, Pharmacol. Rev. 47:331-385, 1995) by using a computer program developed for that purpose. For the 5FC-FCZ combination, the interactions determined by the IC(alpha) generally were in concordance with the interactions determined by the FIC index, but large discrepancies were found between both methods for the 5FC-AB combination. These could mainly be explained by shortcomings in the FIC approach. The in vitro interaction of 5FC-AB demonstrated variable results depending on the tested Candida isolate. In general, the 5FC-FCZ combination was antagonistic against Candida species, but for some Candida isolates synergism was found. For C. neoformans the interaction for both combinations was highly dependent on the tested isolate and the method used. Response surface approach is an alternative method for determining the interaction between antifungal agents. By using this approach, some of the problems encountered with the FIC were overcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183257      PMCID: PMC127432          DOI: 10.1128/AAC.46.9.2982-2989.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.

Authors:  R L White; D S Burgess; M Manduru; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 2.  Combination therapy with antifungal drugs.

Authors:  A Polak
Journal:  Mycoses       Date:  1988       Impact factor: 4.377

Review 3.  Role of pharmacokinetics in the outcome of infections.

Authors:  G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

Review 4.  The search for synergy: a critical review from a response surface perspective.

Authors:  W R Greco; G Bravo; J C Parsons
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

5.  Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

Authors:  R A Larsen; S A Bozzette; B E Jones; D Haghighat; M A Leal; D Forthal; M Bauer; J G Tilles; J A McCutchan; J M Leedom
Journal:  Clin Infect Dis       Date:  1994-10       Impact factor: 9.079

6.  In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans.

Authors:  M A Ghannoum; Y Fu; A S Ibrahim; L A Mortara; M C Shafiq; J E Edwards; R S Criddle
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

7.  Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii.

Authors:  T J Walsh; J Peter; D A McGough; A W Fothergill; M G Rinaldi; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

Review 8.  Clinical aspects of fungal infection in organ transplant recipients.

Authors:  P L Hibberd; R H Rubin
Journal:  Clin Infect Dis       Date:  1994-08       Impact factor: 9.079

Review 9.  Fungal infections in solid-organ transplantation.

Authors:  C V Paya
Journal:  Clin Infect Dis       Date:  1993-05       Impact factor: 9.079

10.  In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans.

Authors:  M H Nguyen; F Barchiesi; D A McGough; V L Yu; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  27 in total

1.  Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole.

Authors:  Javier Afeltra; Roxana G Vitale; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 2.  Antifungal therapy for newborn infants with invasive fungal infection.

Authors:  Linda Clerihew; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

3.  Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.

Authors:  Patrick Schwarz; Guilhem Janbon; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

4.  Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.

Authors:  Vishnu Chaturvedi; Rama Ramani; David Andes; Daniel J Diekema; Michael A Pfaller; Mahmoud A Ghannoum; Cindy Knapp; Shawn R Lockhart; Luis Ostrosky-Zeichner; Thomas J Walsh; Karen Marchillo; Shawn Messer; Amanda R Welshenbaugh; Cara Bastulli; Noreen Iqbal; Victor L Paetznick; Jose Rodriguez; Tin Sein
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

5.  Potent Antifungal Synergy of Phthalazinone and Isoquinolones with Azoles Against Candida albicans.

Authors:  Aaron D Mood; Ilandari Dewage Udara Anulal Premachandra; Stanley Hiew; Fuqiang Wang; Kevin A Scott; Nathan J Oldenhuis; Haoping Liu; David L Van Vranken
Journal:  ACS Med Chem Lett       Date:  2017-01-11       Impact factor: 4.345

6.  In vitro interaction between fluconazole and triclosan against clinical isolates of fluconazole-resistant Candida albicans determined by different methods.

Authors:  Lu Yu; Guanghui Ling; Xuming Deng; Jing Jin; Qi Jin; Na Guo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

7.  Multilaboratory testing of antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent inhibition as the endpoint.

Authors:  Ping Ren; Ming Luo; Shao Lin; Mahmoud A Ghannoum; Nancy Isham; Dan J Diekema; Michael A Pfaller; Shawn Messer; Shawn R Lockhart; Naureen Iqbal; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

8.  In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.

Authors:  Aspasia Katragkou; Matthew McCarthy; Joseph Meletiadis; Vidmantas Petraitis; Patriss W Moradi; Gittel E Strauss; Monique M Fouant; Laura L Kovanda; Ruta Petraitiene; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

9.  In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.

Authors:  Lingmei Sun; Shujuan Sun; Aixia Cheng; Xiuzhen Wu; Yu Zhang; Hongxiang Lou
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

10.  In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Monia Maracci; Annette W Fothergill; Isabella Baldassarri; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.